Stratified medicine in psychiatry: A worrying example or new opportunity in the treatment of anxiety?

Journal of Psychopharmacology

Volumn 27, Issue 2, 2013, Pages 119-122

  Owen, David R ^a   Rupprecht, Rainer ^b   Nutt, David J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

anxiety; neurosteroids; Stratified medicine; translocator protein

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; EMAPUNIL; MEMBRANE PROTEIN; NEUROSTEROID; PLACEBO; PROTEIN TSPO; TETRAGASTRIN; TRAMADOL; UNCLASSIFIED DRUG;

ANXIETY DISORDER; DRUG BINDING SITE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; GENERALIZED ANXIETY DISORDER; GENOTYPE; HUMAN; LOW DRUG DOSE; NONHUMAN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHIATRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SLEEP DISORDER; STRATIFIED MEDICINE; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PSYCHIATRY;

EID: 84872683077     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112443746     Document Type: Review

References (23)

1. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 ; 19: 567-596
2. Baulieu EE, Robel P, Schumacher M. Neurosteroids: Beginning of the story. Int Rev Neurobiol. 2001 ; 46: 1-32
3. Brot MD, Akwa Y, Purdy RH, et al. The anxiolytic-like effects of the neurosteroid allopregnanolone: Interactions with GABA(A) receptors. Eur J Pharmacol. 1997 ; 325: 1-7
4. Carboni E, Wieland S, Lan NC, et al. Anxiolytic properties of endogenously occurring pregnanediols in two rodent models of anxiety. Psychopharmacology (Berl). 1996 ; 126: 173-178
5. Gavish M, Bachman I, Shoukrun R, et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev. 1999 ; 51: 629-650
6. Kreisl WC, Fujita M, Fujimura Y, et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage. 2010 ; 49: 2924-2932
7. Kurumaji A, Nomoto H, Yoshikawa T, et al. An association study between two missense variations of the benzodiazepine receptor (peripheral) gene and schizophrenia in a Japanese sample. J Neural Transm. 2000 ; 107: 491-500
8. Nutt DJ, Ballenger JC, Sheehan D, et al. Generalized anxiety disorder: Comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol. 2002 ; 5: 315-325
9. Owen DR, Howell OW, Tang SP, et al. Two binding sites for [(3)H] PBR28 in human brain: Implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010 ; 30 (9). 1608-1618
10. Owen DR, Gunn RN, Rabiner EA, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 2011a ; 52: 24-32
11. Owen DR, Lewis AJ, Reynolds R, et al. Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse. 2011b ; 65: 257-259
12. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2011c ; 32 (1). 1-5
13. Papadopoulos V. Peripheral-type benzodiazepine/diazepam binding inhibitor receptor: Biological role in steroidogenic cell function. Endocr Rev. 1993 ; 14: 222-240
14. Papadopoulos V, Amri H, Li H, et al. Targeted disruption of the peripheral-type benzodiazepine receptor gene inhibits steroidogenesis in the R2C Leydig tumor cell line. J Biol Chem. 1997 ; 272: 32129-32135
15. Poulsen L, Arendt-Nielsen L, Brosen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther. 1996 ; 60: 636-644
16. Rone MB, Fan J, Papadopoulos V. Cholesterol transport in steroid biosynthesis: Role of protein-protein interactions and implications in disease states. Biochim Biophys Acta. 2009 ; 1791: 646-658
17. Rupprecht R, Holsboer F. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 1999 ; 22: 410-416
18. Rupprecht R, Rammes G, Eser D, et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science. 2009 ; 325: 490-493
19. Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010 ; 9: 971-988
20. Strohle A, Romeo E, di Michele F, et al. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: Preliminary results. Arch Gen Psychiatry. 2003 ; 60: 161-168
21. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (translocator protein 18kDa) in microglia: From pathology to imaging. Prog Neurobiol. 2006 ; 80: 308-322
22. Verleye M, Akwa Y, Liere P, et al. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol Biochem Behav. 2005 ; 82: 712-720
23. Woods MJ, Zisterer DM, Williams DC. Two cellular and subcellular locations for the peripheral-type benzodiazepine receptor in rat liver. Biochem Pharmacol. 1996 ; 51: 1283-1292